| Literature DB >> 29969473 |
Kai B Kaufmann1, Sebastian Heinrich1, Hans Felix Staehle1, Lioudmila Bogatyreva2, Hartmut Buerkle1, Ulrich Goebel1.
Abstract
BACKGROUND: Postoperative complications after lung surgery are frequent, having a detrimental effect on patients' further course. Complications may lead to an increased length of hospital stay and cause additional costs. Several risk factors have been identified but it is still difficult to predict contemporary which patients are at risk. We hypothesized that patients who show an increased inflammatory response at the time of wound closure and 24 hours after surgery are at risk of postoperative complications within 30 days after surgery.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29969473 PMCID: PMC6029786 DOI: 10.1371/journal.pone.0199807
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1CONSORT flow chart.
Postoperative complications.
| Atelectasis | 10 (10%) |
| Pneumonia | 6 (6%) |
| Pleural empyema | 2 (2%) |
| Respiratory failure | 2 (2%) |
| Pulmonary embolism | 2 (2%) |
| Broncho-pleural fistula | 1 (1%) |
| Acute Kidney Injury | 3 (3%) |
| Myocardial infarction | 2 (2%) |
| Atrial fibrillation | 4 (4%) |
| Stroke | 1 (1%) |
| Delirium | 1 (1%) |
| Total complications | 34 (35%) |
| Total amount of patients with postoperative complications | 29 (30%) |
Definition according to the uropean erioperative linical utcome definitions (modified [15]) Data are presented as number of patients and percentage of all analyzed patients.
Patient and surgical characteristics.
| Complications | No complications | |||
|---|---|---|---|---|
| (n = 29) | (n = 67) | |||
| Age [years] | 65 (60–73) | 64 (51–73) | 0.3 | |
| BMI [kg/m2] | 26 (23–29) | 26 (23–29) | 0.9 | |
| Sex [n] | male | 18 (62%) | 35 (52%) | 0.5 |
| female | 11 (38%) | 32 (48%) | 0.5 | |
| ASA [n] | 1 | 0 | 0 | |
| 2 | 3 (10%) | 11 (17%) | 0.54 | |
| 3 | 24 (83%) | 53 (80%) | 0.78 | |
| 4 | 2 (7%) | 2 (3%) | 0.58 | |
| Comorbidity [n] | ||||
| Nicotine dependence | 23 (79%) | 38 (57%) | ||
| Alcohol abuse | 1 (3%) | 7 (10%) | 0.43 | |
| Ischemic heart disease | 8 (28%) | 11 (16%) | 0.27 | |
| Hypertension | 16 (55%) | 31 (46%) | 0.5 | |
| Diabetes mellitus | 4 (14%) | 7 (10%) | 0.73 | |
| Renal function: | ||||
| Creatinine [mg/dl] | 0.86 ± 0.16 | 0.88 ± 0.33 | 0.63 | |
| GFR ml/min [n]: | ||||
| >90 | 8 (28%) | 24 (36%) | 0.49 | |
| 90–60 | 18 (62%) | 35 (52%) | 0.5 | |
| 60–30 | 2 (7%) | 8 (12%) | 0.72 | |
| 30–15 | 1 (3%) | 0 | 0.3 | |
| Preoperative medication [n] | ||||
| Insulin | 1 (3%) | 0 | 0.3 | |
| Oral antidiabetics | 4 (14%) | 5 (8%) | 0.45 | |
| Beta-blocker | 14 (48%) | 18 (27%) | 0.06 | |
| Calciumantagonist | 6 (21%) | 10 (15%) | 0.55 | |
| ACE inhibitors | 8 (28%) | 12 (18%) | 0.29 | |
| ARBs blockers | 1 (3%) | 14 (21%) | ||
| Aspirin | 7 (24%) | 20 (30%) | 0.63 | |
| Clopidogrel | 0 | 1 (1,5%) | 1.0 | |
| Diuretics | 3 (11%) | 10 (15%) | 0.75 | |
| Antiarrhythmics | 0 | 2 (3%) | 1.0 | |
| Bronchodilators | 2 (7%) | 9 (13%) | 0.5 | |
| Cortison | 2 (7%) | 4 (6%) | 1.0 | |
| Indication for surgery [n] | ||||
| Malignancy | 19 (66%) | 39 (58%) | 0.65 | |
| Metastasis | 8 (28%) | 15 (22%) | 0.6 | |
| Others | 2 (6%) | 13 (20%) | 0.2 | |
| Types of surgery [n] | ||||
| Thoracoscopy | 4 (14%) | 28 (42%) | ||
| Thoracotomy | 25 (86%) | 39 (58%) | ||
| Wedge resection | 11 (38%) | 21 (31%) | 0.64 | |
| Segmentectomy | 1 (3%) | 10 (25%) | 0.16 | |
| Lobectomy | 15 (52%) | 33 (49%) | 1.0 | |
| Pneumonectomy | 2 (7%) | 3 (5%) | 0.64 | |
| Respiratory function [%] | ||||
| FEV1 | 68 (54–86) | 80 (66–98) | ||
| VC | 85 (72–104) | 99 (87–111) | ||
| PEF | 69 (52–82) | 77 (61–96) | ||
| Tiffeneau-Index | 64 (52–72) | 64 (55–77) | 0.13 | |
Data are presented as number of patients and percentage within the group, median and interquartile range or mean and standard deviation. ASA = American Society of Anesthesiologists; Crea. = creatinine; GFR = glomerular filtration rate; ACE inhibitors = Angiotensin-converting-enzyme inhibitors; ARBs = Angiotensin-receptor-II blockers; FEV1 = forced expiratory volume in 1 second; VC = vital capacity; PEF = peak expiratory flow.
Perioperative characteristics.
| Complications | No complications | ||
|---|---|---|---|
| (n = 29) | (n = 67) | ||
| Anaesthesia [min] | 280 (220–360) | 245 (185–300) | 0.06 |
| Surgery [min] | 183 (118–269) | 163 (100–202) | 0.1 |
| Norepinephrine [μg/kg/min] | 0.03 (0.02–0.04) | 0.02 (0.01–0.04) | 0.2 |
| Ephedrine [n] | 9 (31%) | 24 (36%) | 0.8 |
| Crystalloids [ml/kg/h] | 5.9 (4.2–7.7) | 6.0 (4.4–7.4) | 0.65 |
| Total crystalloids [ml] | 1850 (1325–3000) | 2000 (1100–2100) | 0.59 |
| Urine output [ml/kg/h] | 0.97 (0.75–1.6) | 0.97 (0.74–1.5) | 0.98 |
| Total urine output [ml] | 350 (250–510) | 360 (260–600) | 0.8 |
| Total blood loss [ml] | 200 (100–300) | 300 (100–500) | 0.2 |
| Fluid balance [ml] | 1350 (900–2380) | 1300 (900–1640) | 0.6 |
| Cardiac Index [l/min/m2] | 2.5 (2.2–3.1) | 2.5 (2.0–3.2) | 0.8 |
| Mean Arterial Pressure [mmHg] | 79 (75–86) | 79 (75–86) | 0.7 |
| Length of hospital stay [days] | 12 (11–17) | 9 (7–11) |
Data are presented as number of patients and percentage or median and interquartile range.
Fig 2Inflammatory cytokine analysis of IL-6, IL-8 and IL-10 pre-operatively (pre-OP), at wound closure (end of surgery) and 24 hours after the end of surgery (24 hours postop).
Red box plots represent the data of the complication group, black box plots represent data of the complication-free group. Data are median and interquartile range. Exact p-values are given.
Fig 3Receiver operating characteristic curves for the development of postoperative complications for inflammatory biomarkers.
T1 = at wound closure; T2 = first postoperative day; (A.) area under the curve = 0.65; 95% confidence interval: 0.51–0.78; (B.) area under the curve = 0.68; 95% confidence interval: 0.54–0.82; (C.) area under the curve = 0.64; 95% confidence interval: 0.52–0.76; (D) area under the curve = 0.63; 95% confidence interval: 0.49–0.77.
Multivariate regression analysis for IL-8.
| Regression coefficient | P Value | Odds Ratio Exp (B) | 95% Confidence interval | ||
|---|---|---|---|---|---|
| FEV1 | 0,027 | 0,283 | 1,027 | 0,978 | 1,078 |
| PEF | 0,018 | 0,342 | 1,018 | 0,981 | 1,056 |
| VC | -0,02 | 0,414 | 0,981 | 0,936 | 1,028 |
| Nicotine | 0,662 | 0,407 | 1,939 | 0,405 | 9,296 |
| ARBs | -2,826 | 0,035 | 0,059 | 0,004 | 0,822 |
| Surgical approach | -2,498 | 0,013 | 0,54 | ||
| IL-8 T1 < = 1. Quartile | -1,672 | 0,087 | 0,188 | 0,028 | 1,277 |
| IL-8 T1 > = 3. Quartile | -0,67 | 0,465 | 0,512 | 0,085 | 3,088 |
| IL-8 T2 < = 1. Quartile | 0,411 | 0,633 | 1,509 | 0,279 | 8,158 |
| IL-8 T2 > = 3. Quartile | 2,073 | 1,314 | 48,069 | ||
FEV1 = forced expiratory volume in 1 second; PEF = peak expiratory flow; VC = vital capacity; IL-8 = interleukin 8; T1 = at the end of surgery at wound closure; T2 = 24 hours after surgery; ARBs = Angiotensin-receptor-II blockers; surgical approach = thoracoscopy vs. thoracotomy.
Multivariate regression analysis for patients with IL-8 and IL-6 levels above the 3rd quartile 24 hours after surgery.
| Regression coefficient | P Value | Odds Ratio Exp (B) | 95% Confidence interval | ||
|---|---|---|---|---|---|
| FEV1 | 0,035 | 0,151 | 1,036 | 0,987 | 1,087 |
| PEF | 0,009 | 0,643 | 1,009 | 0,973 | 1,046 |
| VC | -0,032 | 0,193 | 0,968 | 0,923 | 1,016 |
| Nicotine | 0,776 | 0,296 | 2,173 | 0,506 | 9,321 |
| ARBs | -2,798 | 0,077 | 0,061 | 0,003 | 1,352 |
| Surgical approach | -2,972 | 0,004 | 0,598 | ||
| IL-6 T2 & IL-8 T2 > = 3. Quartile | 4,033 | 2,32 | 1372,701 | ||
FEV1 = forced expiratory volume in 1 second; PEF = peak expiratory flow; VC = vital capacity; IL-6 = interleukin 6; IL-8 = interleukin 8; T2 = 24 hours after surgery; ARBs = Angiotensin-receptor-II blockers; surgical approach = thoracoscopy vs. thoracotomy.